Related Experiment Video
Updated: Aug 19, 2025
07:07
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
12.5K
Mouse Syngeneic Melanoma Model with Human Epidermal Growth Factor Receptor Expression
Tatiana A Slastnikova1, Andrey A Rosenkranz1,2, Alexey V Ulasov1
1Laboratory of Molecular Genetics of Intracellular Transport, Institute of Gene Biology, Russian Academy of Sciences, Moscow 119334, Russia.
Pharmaceutics
|November 26, 2022
Summary
Researchers developed a novel mouse melanoma model expressing human epidermal growth factor receptor (EGFR). This model enables efficient in vivo screening of new EGFR-targeting cancer therapies.
Area of Science:
- Oncology
- Genetics
- Biotechnology
Background:
- Malignant melanoma treatment requires effective epidermal growth factor receptor (EGFR)-targeting agents.
- High-throughput in vivo screening necessitates accessible and cost-effective animal tumor models.
Purpose of the Study:
- To develop a mouse syngeneic melanoma model that expresses human EGFR for drug screening.
- To validate the functionality and characteristics of the developed model.
Main Methods:
- Cloudman S91 clone M3 mouse melanoma cells were genetically modified using lentiviral transduction to express human EGFR.
- The modified M3-EGFR cells underwent rigorous selection, in vitro and in vivo testing, including radioligand assays and immunohistochemistry.
Main Results:
- The M3-EGFR model confirmed specific binding and internalization of epidermal growth factor (EGF) and EGFR-targeted nanotransporters.
- The human EGFR expression was maintained in vivo without altering the tumorigenicity of the cells in DBA/2J mice.
Conclusions:
- A novel, first-of-its-kind mouse syngeneic melanoma model with stable in vivo expression of human EGFR has been successfully established.
- This model serves as a valuable platform for preclinical evaluation of EGFR-targeted therapies for melanoma.
